Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07480356 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder (Urothelial, Transitional Cell) Cancer
Non-Muscle Invasive Bladder Carcinoma
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Interventions

DRUG: TARA-002
DRUG: Investigator's Choice of Intravesical Chemotherapy

Sponsor

Protara Therapeutics